Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 67

Results For "commercial"

1732 News Found

AstraZeneca appoints Iskra Reic as Executive Vice President, International
People | December 06, 2024

AstraZeneca appoints Iskra Reic as Executive Vice President, International

Iskra has held leadership positions across Central & Eastern Europe, Eurasia, Middle East & Africa at AstraZeneca


Granules India update on USFDA inspection at Gagillapur facility
News | December 05, 2024

Granules India update on USFDA inspection at Gagillapur facility

Granules has undertaken a proactive, voluntary and comprehensive remediation plan to address the six form 483 observations raised by the USFDA


Ann-Xiaoyan Li appointed Group CFO and MD of Romaco Group
People | December 04, 2024

Ann-Xiaoyan Li appointed Group CFO and MD of Romaco Group

She will be responsible in this role for Finance & Controlling, HR Services and IT Management at Romaco Holding


Dr. Reddy's launches Toripalimab in India
News | December 01, 2024

Dr. Reddy's launches Toripalimab in India

The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma


Senores Pharmaceuticals launches Ivermectin Tablets in US with Dr. Reddy's Laboratories
News | November 28, 2024

Senores Pharmaceuticals launches Ivermectin Tablets in US with Dr. Reddy's Laboratories

The product will be marketed by Dr. Reddy's


Azenta obtains regulatory approval for clinical long-read whole genome sequencing test
Biotech | November 22, 2024

Azenta obtains regulatory approval for clinical long-read whole genome sequencing test

Performed within GENEWIZ from Azenta Life Sciences' CLIA-certified and CAP-accredited state-of-the-art clinical genomics laboratory


European Commission approves Pfizer’s HYMPAVZI for treatment of severe Hemophilia A or B without inhibitors
Drug Approval | November 21, 2024

European Commission approves Pfizer’s HYMPAVZI for treatment of severe Hemophilia A or B without inhibitors

HYMPAVZI’s approval is based on Phase 3 study results demonstrating non-inferiority and superiority compared to routine prophylaxis in eligible patients with hemophilia A or B without inhibitors


Indegene announces new Center in Hyderabad
Digitisation | November 20, 2024

Indegene announces new Center in Hyderabad

With 6 operation hubs and 18 offices across North America, Europe, and Asia, Indegene’s client base includes the world’s top 20 biopharma companies


DKSH and Abcam join forces to advance life science research in Vietnam
Supply Chain | November 19, 2024

DKSH and Abcam join forces to advance life science research in Vietnam

This partnership is set to meet the growing demand for innovative life science research solutions in the Vietnamese market


Shilpa Pharma Lifesciences received CEP from EDQM for API, Octreotide
Drug Approval | November 19, 2024

Shilpa Pharma Lifesciences received CEP from EDQM for API, Octreotide

Octreotide is synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid phase synthesis